Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some …
WEB1 day ago · In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $63.13, with a +1.94% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0 ...
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise — A …
WEB2 days ago · Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...
Why Viking Therapeutics Stock Was So Healthy on Wednesday
WEB1 day ago · Viking Therapeutics (NASDAQ: VKTX), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's ...
Why Viking Therapeutics Stock Was So Healthy on Wednesday
WEB1 day ago · Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday.The company's share ...
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines …
WEBGet the latest news and analysis on Viking Therapeutics, a biotech company developing obesity and NASH drugs. See how VKTX stock performed in the market, what analysts predicted, and what...
Viking Therapeutics - Press Releases
WEBJul 24, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Jul 24, 2024
News & Events - Viking Therapeutics InvestorRoom
WEBSAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the ...
Viking Therapeutics stock jumps on weight loss injection trial plans
WEBIt brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
News & Events - Viking Therapeutics InvestorRoom
WEBNews & Events. Back. Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 ... (NASDAQ: VKTX), a clinical-stage …
Viking Therapeutics Announces Completion of Enrollment in …
WEB/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), ... as well as new data demonstrating VK2735's impact on liver fat and plasma lipids. Notably, after four …